Compare Atlassian Corporation PLC (TEAM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs TG Therapeutics Inc — how do they compare? Atlassian Corporation PLC trades at $154.73 (market cap $39.10B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Atlassian Corporation PLC is far larger — about 5.1× TG Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| TEAM | TGTX | |
|---|---|---|
Market Cap | $39.10B | $7.64B |
Sector | Technology | Health |
52-Week High | $182.36 | $59.06 |
52-Week Low | $57.15 | $26.94 |
Enterprise Value | $39.09B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $155.15, up 2.16% with strong momentum following a 35% surge post-earnings. The stock shows bullish technical signals with moving averages supporting upward trends, though RSI indicates overbought conditions. Fundamentally, revenue growth remains robust at 28% YoY in Q4 2026, with cloud revenue accelerating to 31% and the company achieving its first full year of GAAP profitability. Analyst sentiment is overwhelmingly positive with 67% buy ratings and a $161.93 consensus target.
Outlook remains favorable with AI platform adoption and enterprise deal expansion driving growth, though valuation metrics appear stretched with EV/EBITDA at 184x. Key risks include competitive pressures in software and execution challenges in maintaining cloud momentum. The stock's proximity to 52-week highs suggests potential for consolidation near current levels.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
